The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Mechanism of indinavir-induced hyperbilirubinemia
Open accessAbstract
Indinavir is a viral protease inhibitor used for the treatment of HIV infection. Unconjugated hyperbilirubinemia develops in up to 25% of patients receiving indinavir, prompting drug discontinuation and further clinical evaluation in some instances. We postulated that this side-effect is due to indinavir-mediated impairment of bilirubin UDP-glucuronosyltransferase (UGT) activity and would be most pronounced in individuals with reduced hepatic enzyme levels, as occurs in ≈10% of the population manifesting Gilbert's syndrome. This hypothesis was tested in vitro , in the Gunn rat model of UGT deficiency, and in HIV-infected patients with and without the Gilbert's polymorphism. Indinavir was found to competitively inhibit UGT enzymatic activity ( K I = 183 μM) while concomitantly inducing hepatic bilirubin UGT mRNA and protein expression. Although oral indinavir increased plasma bilirubin levels in wild-type and heterozygous Gunn rats, the mean rise was significantly greater in the latter group of animals. Similarly, serum bilirubin increased by a mean of 0.34 mg/dl in indinavir-treated HIV patients lacking the Gilbert's polymorphism versus 1.45 mg/dl in those who were either heterozygous or homozygous for the mutant allele. Whereas saquinavir also competitively inhibits UGT activity, this drug has not been associated with hyperbilirubinemia, most likely because of the higher K I (360 μM) and substantially lower therapeutic levels as compared with indinavir. Taken together, these findings indicate that elevations in serum-unconjugated bilirubin associated with indinavir treatment result from direct inhibition of bilirubin-conjugating activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Self-citationGulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371102 · Cited by 1,885
Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease
Tukey, R. H., & Strassburg, C. P. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.581 · Cited by 1,523
Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N. J., Jansen, P. L. M., Elferink, R. P. J. O., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331802 · Cited by 1,447
Active human immunodeficiency virus protease is required for viral infectivity
Kohl, N. E., Emini, E. A., Schleif, W. A., Davis, L. J., Heimbach, J. C., Dixon, R. A., Scolnick, E. M., & Sigal, I. S. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4686 · Cited by 1,307
Tam, J. P. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.15.5409 · Cited by 1,251
Beutler, E., Gelbart, T., & Demina, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8170 · Cited by 853
HIV-1 protease inhibitors. A review for clinicians
Deeks, S. G. (1997) · JAMA · doi:10.1001/jama.277.2.145 · Cited by 675
Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome
Monaghan, G., Ryan, M., Hume, R., Burchell, B., & Seddon, R. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91273-8 · Cited by 585
HIV-1 Protease Inhibitors: A Review for Clinicians
Deeks, S. G. (1997) · JAMA · doi:10.1001/jama.1997.03540260059037 · Cited by 434
The ready isomerization of bilirubin IX-α in aqueous solution
McDonagh, A. F., & Assisi, F. V. L. (1972) · Biochemical Journal · doi:10.1042/bj1290797 · Cited by 234
Heirwegh, K. P. M., Van De Vijver, M., & Fevery, J. (1972) · Biochemical Journal · doi:10.1042/bj1290605 · Cited by 225
A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
Stein, D. S., Fish, D. G., Bilello, J. A., Preston, S. L., Martineau, G. L., & Drusano, G. L. (1996) · AIDS · doi:10.1097/00002030-199605000-00006 · Cited by 172
Seppen, J., Bosma, P. J., Goldhoorn, B. G., Bakker, C. T., Chowdhury, J. R., Chowdhury, N. R., Jansen, P. L., & Oude Elferink, R. P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117604 · Cited by 171
Raijmakers, M. T. M., Jansen, P. L. M., Steegers, E. A. P., & Peters, W. H. M. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80268-8 · Cited by 170
Lin, J. H., Chiba, M., Balani, S. K., Chen, I., Kwei, G. Y., Vastag, K., & Nishime, J. A. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08414-4 · Cited by 153
Iyanagi, T., Watanabe, T., & Uchiyama, Y. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)30079-1 · Cited by 108
Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.
Balani, S. K., Woolf, E., Hoagland, V. D., Sturgill, M. G., Deutsch, P., Yeh, K. C., & Lin, J. H. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08479-x · Cited by 99
Sampietro, M., Lupica, L., Perrero, L., Comino, A., di Montemuros, F. M., Cappellini, M. D., & Fiorelli, G. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.4113228.x · Cited by 98
pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
Lin, J. H., Chen, I. W., Vastag, K., & Ostović, D. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06651-6 · Cited by 79
Kaul, D. R., Cinti, S. K., Carver, P. L., & Kazanjian, P. H. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.4.281.30937 · Cited by 67
McPhee, F., Caldera, P., Bemis, G. W., McDonagh, A. F., Kuntz, I. D., & Craik, C. S. (1996) · Biochemical Journal · doi:10.1042/bj3200681 · Cited by 64
Strassburg, C. P., & Manns, M. P. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80285-8 · Cited by 49
Whitmer, D. I., Russell, P. E., Ziurys, J. C., et al. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38370-9 · Cited by 14
Cited by
A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters
Ramaiah, S. K. (2007) · Food and Chemical Toxicology · doi:10.1016/j.fct.2007.06.007 · Cited by 494
Hall, A. P., Elcombe, C. R., Foster, J. R., Harada, T., Kaufmann, W., Knippel, A., Küttler, K., Malarkey, D. E., Maronpot, R. R., Nishikawa, A., et al. (2012) · Toxicologic Pathology · doi:10.1177/0192623312448935 · Cited by 427
Bilirubin in clinical practice: a review
Fevery, J. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01716.x · Cited by 374
Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management
Núñez, M. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.027 · Cited by 313
Zhang, D., Chando, T. J., Everett, D. W., Patten, C. J., Dehal, S. S., & Humphreys, W. G. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005447 · Cited by 286
Metadata
- Authors
- Zucker, S. D., Qin, X., Rouster, S. D., Yu, F., Green, R. M., Keshavan, P., Feinberg, J., & Sherman, K. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-10-16
- Volume
- 98
- Issue
- 22
- Pages
- 12671-12676
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2017011289
- Cited by
- 262
- References
- 24
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.